Article

Significant Benefit of Everolimus In a Patient With Urothelial Bladder Cancer Harboring A Rare M1043I Mutation of PIK3CA

2021-02-22

Abstract excerpt

Urothelial bladder cancer (UBC) is a common malignancy with significant mortality worldwide. However, treatment options of UBC were mainly chemotherapy and immunotherapy since few targeted agents had shown efficacy in UBC. In recent studies, everolimus has showed antitumor activity in patients harboring aberrations in PI3K/Akt/mTOR pathway in multiple tumor types. Here we report a patient with metastatic UBC harbo...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 6d0716dc-e223-5436-8455-234551ce716b
DOI: 10.21203/rs.3.rs-216259/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Significant Benefit of Everolimus In a Patient With Urothelial Bladder Cancer Harboring A Rare M1043I Mutation of PIK3CADOI 10.21203/rs.3.rs-216259/v1Read

Significant benefit of everolimus in a patient with urothelial bladder cancer harboring a rare M1043I mutation of PIK3CA.Semantic proximity Read

Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations.Semantic proximity Read

Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma.Semantic proximity Read

Emerging therapeutic targets in bladder cancer.Semantic proximity Read

Genomic Alterations of Signaling and DNA Damage Repair Pathways in Non-Muscle Invasive Bladder Cancer.Semantic proximity Read

A Muscle-Invasive Bladder Cancer Patient With High Tumor Mutational Burden and RB1 Mutation Achieved Bladder Preservation Following Chemotherapy Combined With Immunotherapy: A Case Report.Semantic proximity Read

Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients.Semantic proximity Read

Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study.Semantic proximity Read

TSC1 involvement in bladder cancer: diverse effects and therapeutic implicationsSemantic proximity Read

AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17KSemantic proximity Read

Actionable mutations in muscle-invasive bladder cancer.Semantic proximity Read

Genome Sequencing Identifies a Basis for Everolimus SensitivitySemantic proximity Read